TABLE 1

Experiment 1: A-B and B-A receiver concentrations at 90 min and apparent permeabilities for 10 compounds in MDCK cells and MDR1-MDCK cells

Drug	Cell Type	C_r,AB	C_r,BA	P_app,AB	P_app,BA	ER
		μM		10⁻⁶ cm/s
Amprenavir	MDCK	0.054	1.5	2.7	25	8.9
Amprenavir	MDR1	0.0057	4.2	0.29	70	240
Atorvastatin	MDCK	0.0089	0.037	0.45	0.62	1.4
Atorvastatin	MDR1	0.0034	1.7	0.17	29	170
Digoxin	MDCK	0.0039	0.27	0.19	4.6	24
Digoxin	MDR1	0.0016	0.59	0.078	9.9	130
Labetalol	MDCK	0.0051	0.036	0.26	0.6	2.3
Labetalol	MDR1	0.0036	1.6	0.18	26	150
Loperamide	MDCK	0.026	0.9	1.3	15	11
Loperamide	MDR1	0.005	3.1	0.25	52	210
Minoxidil	MDCK	0.015	0.047	0.74	0.79	1.1
Minoxidil	MDR1	0.021	0.17	1.1	2.8	2.6
Pitavastatin	MDCK	0.012	0.024	0.62	0.4	0.65
Pitavastatin	MDR1	0.014	2.3	0.7	39	56
Repaglinide	MDCK	0.26	1.2	13	21	1.6
Repaglinide	MDR1	0.012	4.1	0.6	69	120
Simvastatin	MDCK	0.061	0.44	3.1	7.4	2.4
Simvastatin	MDR1	0.04	0.62	2.0	10	5.2
Verapamil	MDCK	0.36	1.9	18	33	1.8
Verapamil	MDR1	0.03	4.9	1.5	83	55

C_r,AB, concentration in receiver (basolateral side) upon apical dosing; C_r,BA, concentration in receiver (apical side) upon basolateral dosing; P_app,BA, apparent permeability calculated from B-A experiments; P_app,AB, apparent permeability calculated from A-B experiments; ER, efflux ratio.